Delving into the Latest Updates on Carrimycin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Biotechmycin, Biotechspiramycin, Levocarrimycin

+ [8]

Target

50S subunit

Action

inhibitors

Mechanism

50S subunit inhibitors(50S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Bacterial Infections

Inactive Indication

COVID-19

Originator Organization

Beijing Capital Science & Technology Group Co., Ltd.

Institute of Medical Biology,Chinese Academy of Medical Sciences

Active Organization

Shanghai Tonglian Pharmaceutical Co.,Ltd.

Inactive Organization

Shenyang Tonglian Group Co. Ltd.

License Organization

Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences

Shenyang Tonglian Group Co. Ltd.

Drug Highest PhaseApproved

First Approval Date

China (24 Jun 2019),

Bacterial Infections

RegulationSpecial Review Project (China), Priority Review (China)

Login to view timeline

Recently, the exploration of potential therapeutic applications for approved pharmaceuticals arouses significant interest. Messenger RNA (mRNA), which intricately involves in biological processes and reflects the physiological states of organisms, serves as a robust biomarker for investigating the impacts of drugs on cellular environments in both cell biology and clinical research. Nanopore technology has demonstrated to be a versatile tool for multiple applications, including disease diagnostics, environmental monitoring, and food surveillance. Herein, we proposed a protease-hydrolysis-based approach for mRNA quantification within protein nanopores. In this context, a type of peptide-DNA chimera probe was synthesized through a click reaction. The presence of target mRNA molecules promoted the formation of a sandwich complex between the target and probes, which in turn enabled the protease-mediated cleavage of the peptide segment. Then, the cleaved peptide fragments served as external probes for nanopore analysis. To optimize the measurement conditions, the effects of voltage bias and buffer pH values on the performance of the nanopore sensor were systematically investigated. The proposed nanopore sensor was further performed to assess cellular samples, which showed a ∼4-fold reduction in P2RX7 mRNA levels in the SMMC-7721 cell line pre- and post-carrimycin therapy. This outcome indicated the anti-cancer efficacy of carrimycin, and the result was comparable to that of qRT-PCR analysis, highlighting its reliable performance in real sample detection. This protein nanopore mRNA sensor successfully addressed high molecular weight and complex background species in the quantification of mRNA. Our study introduced an innovative methodology for cellular mRNA quantification to explore the potential therapeutic application of pharmaceuticals, while also offering a new approach for mRNA quantification in disease diagnosis, toxicological assessment, and personalized medicine.

01 Apr 2025·European Journal of Medicinal Chemistry

Synthesis and evolution of 16-membered macrolide carrimycin derivatives as a novel class of anti-HCoV-OC43 agents targeting viral FSE RNA

Article

Author: Gong, Yue ; Li, Jianrui ; Li, Yinghong ; He, Weiqing ; Wu, Zhiyun ; Li, Jiayu ; Yu, Zhihui ; Duan, Qionglu ; Zhong, Xiuli ; Li, Hongying ; Liu, Yonghua ; Meng, Runze ; Peng, Zonggen ; Song, Danqing

We first demonstrate that carrimycin, as an antibiotic, shows broad-spectrum anti-coronavirus activity by targeting frameshifting element (FSE) RNA. Herein, taking carrimycin as the lead, 26 new 16-membered macrolides were synthesized and evaluated for antiviral activity against coronavirus strains. Compound 2d exhibited the elevated antiviral efficacy against HCoV-OC43 and HCoV-229E with EC₅₀ values of 0.85 μM and 1.45 μM by directly targeting coronaviral FSE RNA pseudoknot. Molecular simulations revealed that the introduction of a 4″-substituent transforms the macrocyclic core into U-shaped conformation, enabling the higher binding with FSE. Meanwhile, using thermal proteome profiling (TPP) technology, we identified DIS3L2 as a potential host target, which probably assisted 2d to exert the antiviral effect. Therefore, the 16-membered macrolides constituted a new class of RNA inhibitors against coronaviruses, and 2d owns a dual-target mechanism that acts on both viral FSE RNA and host DIS3L2.

01 Mar 2025·Journal of Pharmaceutical Analysis

Isovalerylspiramycin I alleviates liver injury and liver fibrosis by targeting the nucleotide-binding protein 2 (NUBP2)-vascular non-inflammatory molecule-1 (VNN1) pathway

Article

Author: Niu, Weiping ; Li, Yang ; Guo, Simin ; Zhang, Na ; Niu, Weixiao ; He, Weiqing ; He, Hongwei ; Li, Yiming

Liver fibrosis is a vital cause of morbidity in patients with liver diseases and developing novel anti-fibrotic drugs is imperative. Isovalerylspiramycin I (ISP I) as a major component of carrimycin applied to upper respiratory infections, was first found to possess anti-fibrotic potential. The present study aims to evaluate the functions and mechanisms of ISP I in protecting against liver fibrosis. According to our results, ISP I not only reduced the expressions of fibrogenic markers in LX-2 cells but also appeared great protective effects on liver injury and liver fibrosis in bile duct ligation (BDL) rats and carbon tetrachloride (CCl₄) mice. We proved that nucleotide-binding protein 2 (NUBP2) was the direct target of ISP I. ISP I through targeting NUBP2, increased the amount of vascular non-inflammatory molecule-1 (VNN1) on the cell membrane, which will inhibit oxidative stress and fibrosis. Simultaneously, the original carrimycin's protective effect on liver damage and fibrosis was verified. Therefore, our study provides potential agents for patients with liver fibrosis-related diseases, and the clear mechanism supports wide application in the clinic.

100 Deals associated with Carrimycin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	China	Shanghai Tonglian Pharmaceutical Co.,Ltd.	24 Jun 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	Argentina	Shenyang Tonglian Group Co. Ltd.	30 Mar 2021
COVID-19	Phase 2	Mexico	Shenyang Tonglian Group Co. Ltd.	30 Mar 2021
COVID-19	Phase 2	Ukraine	Shenyang Tonglian Group Co. Ltd.	30 Mar 2021
COVID-19	Phase 2	Brazil	Shenyang Tonglian Group Co. Ltd.	30 Mar 2021
COVID-19	Phase 2	Philippines	Shenyang Tonglian Group Co. Ltd.	30 Mar 2021
COVID-19	Phase 2	United States	Shenyang Tonglian Group Co. Ltd.	30 Mar 2021